Executive Summary: Key Legal and Evidentiary Issues

• The applicants sought to invalidate or postpone a shareholders’ meeting under sections 106 and 107 of the OBCA.

• Allegations were raised about improper proxy solicitation, misleading public disclosures, and unfair corporate governance practices.

• The court assessed whether MediPharm’s procedures breached shareholder rights or corporate by-laws.

• Evidence showed the applicants' own conduct lacked transparency and involved attempts to take control of the board.

• The judge found the AGM process met statutory and procedural requirements and was not oppressive or unfair.

• All claims were dismissed, with costs awarded against the applicants.

Background and shareholder dispute

Apollo Technology Capital Corporation and Peter Lacey, minority shareholders of MediPharm Labs Corp., brought an urgent application seeking to postpone MediPharm’s 2024 annual general meeting (AGM) or to invalidate its outcomes. They claimed that MediPharm’s directors engaged in unfair practices, including improper proxy solicitation, failure to disclose key information to shareholders, and denial of access to the company's shareholder list.

Apollo and Lacey also challenged the legitimacy of MediPharm’s circular, claiming it was misleading and crafted to entrench the incumbent board. They asserted that as significant shareholders with a proposed slate of new directors, they were denied a fair opportunity to participate in the governance process. The application was filed under sections 106 and 107 of the Ontario Business Corporations Act (OBCA), which govern the calling and conduct of shareholder meetings.

Contested AGM and allegations of procedural unfairness

The applicants had submitted a dissident circular and intended to propose an alternative slate of directors. MediPharm resisted, citing deficiencies in the applicants’ circular, concerns about regulatory compliance, and the need to adhere strictly to its corporate by-laws and OBCA requirements.

During the contested AGM process, MediPharm granted limited access to shareholder information and enforced procedural controls designed to ensure regulatory and legal compliance. Apollo and Lacey claimed that these controls effectively shut them out of the process and denied their right to influence the vote. They further alleged that the company’s disclosures created an uneven playing field and misled other shareholders.

Court's analysis of corporate governance and fairness

Justice Steele of the Ontario Superior Court of Justice reviewed the allegations under the framework of the OBCA and applicable corporate law principles. The court emphasized the importance of shareholder democracy but noted that regulatory compliance, procedural fairness, and internal by-law enforcement are equally essential to maintaining corporate integrity.

The judge found that MediPharm had not acted oppressively, unfairly, or in bad faith. The company had legitimate concerns about regulatory compliance and had made good-faith efforts to accommodate the applicants’ requests within reasonable limits. Justice Steele also observed that Apollo and Lacey failed to act transparently and had adopted an aggressive posture that undermined their own claims of procedural unfairness.

Outcome and costs

The court dismissed the application in its entirety. It found that the shareholders' meeting had been properly convened and conducted, and that the results—including the election of directors—were valid. The applicants' claims about misleading disclosure and unfair proxy practices were unsupported by the evidence.

Justice Steele awarded costs against the applicants, reinforcing that shareholder disputes must be pursued responsibly and in line with corporate governance norms. The decision serves as a reminder that while shareholder rights are protected under law, they do not override the need for orderly, lawful, and transparent corporate administration.